Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRI Contrast: Gadobenate Dimeglumine vs Gadopentetate Dimeglumine for Residual Pituitary Adenoma
2006-006851-11Phase 4Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Feb 2007
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of gadobenate dimeglumine and gadopentetate dimeglumine in pituitary adenoma (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Superiority of GD-BOBPTA vs GD-DTPA in defining residual pituitary adenoma. Started Feb 2007; status: completed.
02
Drugs
gadobenate dimegluminegadopentetate dimeglumine
03
Conditions
pituitary adenoma
Beyond the preview
Go deeper on 2006-006851-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006851-11.